Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

Regarding PD-1/PD-L1 inhibitors, the analysis of safety was based on 27 trials. The monotherapy such as atezolizumab (OR = 0.24; 95% CI: 0.16–0.35), nivolumab (OR = 0.32; 95% CI: 0.26–0.41), ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in ...

Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics ...

Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...

Cancer treatment is undergoing a revolution, and immunotherapy is leading the charge. Unlike traditional methods like ...

The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of 11.1%, ...